Cargando…

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?

BACKGROUND: Variable disease progression confounds accurate prognosis in Fabry disease. Evidence supports the long-term benefit of early intervention with disease-specific therapy, but current guidelines recommend treatment initiation based on signs that may present too late to avoid irreversible or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hughes, Derralynn A., Aguiar, Patrício, Lidove, Olivier, Nicholls, Kathleen, Nowak, Albina, Thomas, Mark, Torra, Roser, Vujkovac, Bojan, West, Michael L., Feriozzi, Sandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822651/ https://www.ncbi.nlm.nih.gov/pubmed/35135579 http://dx.doi.org/10.1186/s13023-022-02181-4

Ejemplares similares

Early indicators of disease progression in Fabry disease that may indicate the need for disease-specific treatment initiation: findings from the opinion-based PREDICT-FD modified Delphi consensus initiative
por: Hughes, Derralynn A, et al.
Publicado: (2020)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
por: Bichet, Daniel G., et al.
Publicado: (2023)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
por: Wanner, Christoph, et al.
Publicado: (2020)

Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
por: Waldek, Stephen, et al.
Publicado: (2014)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

Biomarkers of Fabry Nephropathy: Review and Future Perspective
por: Levstek, Tina, et al.
Publicado: (2020)

Podocyturia in Fabry disease: a 10-year follow-up
por: Vujkovac, Bojan, et al.
Publicado: (2021)

Urinary-derived extracellular vesicles reveal a distinct microRNA signature associated with the development and progression of Fabry nephropathy
por: Levstek, Tina, et al.
Publicado: (2023)

Fabry disease: the many faces of a single disorder
por: Torra, Roser, et al.
Publicado: (2012)

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023)

Paricalcitol as an Antiproteinuric Agent Can Result in the Deterioration of Renal and Heart Function in a Patient with Fabry Disease
por: Keber, Tajda, et al.
Publicado: (2017)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Urinary Extracellular Vesicles and Their miRNA Cargo in Patients with Fabry Nephropathy
por: Levstek, Tina, et al.
Publicado: (2021)

New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases
por: Mignani, Renzo, et al.
Publicado: (2018)

New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases
por: Mignani, Renzo, et al.
Publicado: (2019)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease
por: Mauhin, Wladimir, et al.
Publicado: (2019)

Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
por: Goláň, Lubor, et al.
Publicado: (2015)

Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
por: Gal, Andreas, et al.
Publicado: (2011)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Fabry nephropathy: 5 years of enzyme replacement therapy—a short review
por: Barbey, Frédéric, et al.
Publicado: (2008)

The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease
por: Furlano, Mónica, et al.
Publicado: (2022)

Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation
por: Hughes, Derralynn, et al.
Publicado: (2023)

Endocrine disorders in patients with Fabry disease: insights from a reference centre prospective study
por: Bothou, Christina, et al.
Publicado: (2021)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
por: Riccio, Eleonora, et al.
Publicado: (2020)

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy
por: Warnock, David G, et al.
Publicado: (2015)

COVID-19 in Fabry disease: a reference center prospective study
por: Bothou, Christina, et al.
Publicado: (2022)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Measures to mitigate disruption due to the COVID-19 pandemic of the MODIFY phase 3 pivotal trial in patients with Fabry disease
por: Frey, Aline, et al.
Publicado: (2021)

Characteristics of communication guidelines that facilitate or impede guideline use: a focus group study
por: Veldhuijzen, Wemke, et al.
Publicado: (2007)

α-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response
por: Consolato, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aj9r0tdf3oen9cqc4o2p85lbn3